AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session Across the COAST 1, COAST 2, and SHORE phase 3 studies, amlitelimab, dosed either Q4W or Q12W, showed progressively increasing efficacy, with no evidence of plateau at Week 24 across endpointsData reinforce potential for Q12W dosing from the start Paris, March 28, 2026. Positive results from three phase 3 studies of amlitelimab, a fully human non-T cell depleting monoclonal antibody t ...

Stock Market Week Ahead: Scarcity Narratives And Naval Tactics| Investor's Business Daily BREAKING: Major Indexes Fall For Fifth Straight Week Stock market investors don't like leaving money on the table heading into weekends lately. That showed clearly on Thursday and Friday, when the Nasdaq and S&P 500 posted a 'cut and run' finish to the week. The result left both dangling at their lowest levels since August. Neither showed any sign of beginning to form a bottom. All three major indexes are now mo ...

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced long-term efficacy and safety data from a two-year long open-label extension (OLE) study of investigational plozasiran supporting its potential as therapeutic solution for a diverse spectrum of patients with hypertriglyceridemia (HTG). The data were presented by Dr. Christie M. Ballantyne, MD, professor at Baylor College of Medicine, member of the Texas Heart Institute at Baylor, and Principal Inve. ...

New York, New York--(Newsfile Corp. - March 28, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline.SO WHAT: If you purchased Aquestive securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency ...

ICOTYDE achieved high levels of complete skin clearance up to Week 52 with no new safety signals2,a "Introducing a oncedaily targeted oral peptide for treating moderatetosevere plaque psoriasis offers patients an option with a unique combination of benefits and a favorable safety profile," said Linda Stein Gold, M.D., Director of Dermatology Clinical Research at Henry Ford Health and ICONICADVANCE study investigator.c "The results from oneyear studies show encouraging outcomes for patients as they navigate ...

PPH ETF: Drug Pricing Policy and Eli Lilly Concentration Are the Two Risks to Watch in 2026 - 24/7 Wall St. S&P 5006,362.40 -2.11% Nikkei 22551,507.00 -2.23% Investing PPH ETF: Drug Pricing Policy and Eli Lilly Concentration Are the Two Risks to Watch in 2026 By Michael WilliamsPublished Mar 28, 7:15AM EDT Quick Read VanEck Pharmaceutical ETF (PPH) is 17.91% concentrated in Eli Lilly (LLY), which has fallen 16% year-to- date as generic GLP-1 competition and patent expirations in emerging markets threaten ...

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Cobenfy--Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy. ...

Despite its leadership in the weight-loss medicine market, Eli Lilly (LLY 2.09%) is not performing well this year, with its shares down 15% to date. Some worry that the drugmaker will eventually face stiff competition in its core niche, eroding its pricing power and profits. However, Eli Lilly has several strengths that should help it perform well over the medium term, even beyond its deep pipeline. Let's look at one reason the stock could deliver strong returns through the next five years. Eli Lilly's exp ...

Wave Life Sciences原本想讲一个和GLP-1不一样的故事。它押注的WVE-007不是传统减肥药，也不是又一个GLP-1变体，而是一款靶向 INHBE的GalNAc-siRNA，希望通过压低Activin E，在减脂的同时尽量保住肌肉，甚至把给药频率拉低到一年一到两次。这个方向的吸引力很 明显：如果GLP-1解决的是减得够不够多，那么WVE-007想回答的是能不能减得更聪明。但第一份真正摆上台面的数据，并没有给市场足够信 心。Wave在3月26日公布INLIGHT一期中期结果后，股价当天一度暴跌58%，收盘跌幅约50%。 真正让市场失望的，是减重数字太弱。根据公司披露，在6个月随访后，单次240 mg剂量的WVE-007经安慰剂校正后的体重降幅只有0.9%。这 个数据本身并不意味着药物完全无效，但放在当前减肥药赛道里，几乎很难支撑下一代重磅品种的估值叙事。尤其是在GLP-1时代，投资人已 经被更高的减重数字教育过一轮，面对不到1%的安慰剂校正减重幅度，市场的第一反应只能是撤退。 如果更细拆数据，WVE-007并不是一无是处。240 mg组在6个月时，内脏脂肪经安慰剂校正后下降14.3%，总脂肪下 ...

整理 | GLP1减重宝典内容团队 3月27日，诺和诺德宣布，美国食品药品监督管理局已批准Awiqli®（依柯胰岛素注射液，700单位/毫升）上市，用于作为饮食和运动的辅助手 段，改善成人2型糖尿病患者的血糖控制。该药物也成为美国首款且目前唯一一款每周一次给药的长效基础胰岛素。 此次获批的意义，不在于这款产品第一次在全球上市，而在于它终于拿下了美国市场。Awiqli此前已在中国获批用于成人2型糖尿病，也已在加 拿大、瑞士等海外市场获批。 FDA此次批准，基于ONWARDS 3a期临床项目结果。该项目围绕每周一次Awiqli用于2型糖尿病治疗展开，包含4项随机、活性对照、目标治疗 试验，共纳入约2680例血糖控制不佳的成人2型糖尿病患者。研究中，Awiqli与餐时胰岛素联用，或与常用口服降糖药和/或GLP-1受体激动剂 联用。 从结果来看，Awiqli在关键临床试验中达到了降低糖化血红蛋白这一主要终点，整体安全性特征与每日基础胰岛素类别总体一致。对患者而 言，这款产品最大的变化，是把原本每周7次的基础胰岛素注射，减少为每周1次，为需要长期胰岛素治疗的2型糖尿病患者提供了新的治疗选 择。 *本文仅供医疗卫生专业人 ...